Back to top
more

vTv Therapeutics (VTVT)

(Real Time Quote from BATS)

$24.36 USD

24.36
3,852

+0.20 (0.82%)

Updated Apr 23, 2024 03:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VTVT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

vTv Therapeutics Inc. [VTVT]

Reports for Purchase

Showing records 1 - 20 ( 44 total )

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/17/2023

Company Report

Pages: 4

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/06/2023

Daily Note

Pages: 3

Azeliragon Receives FDA Approval For Clinical Trials in Glioblastoma and Brain Metastases; Reiterate Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/14/2022

Company Report

Pages: 4

Expecting New Leadership and Partnership to Accelerate TTP399 Pivotal Study; Reiterate Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

08/19/2022

Company Report

Pages: 5

TP399 Phase 3 Trials on Track for 4Q22; Reiterate Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

01/19/2022

Company Report

Pages: 4

TTP399 Represents an Attractive Licensing Opportunity; Reiterate Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/13/2021

Daily Note

Pages: 3

Fireside Chat

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/10/2021

Company Report

Pages: 4

TTP399 on Track to Begin Phase 2 Study in Early 2022; Reit Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for VTVT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

09/24/2021

Daily Note

Pages: 3

Positive Results Position HPP737 on Track to Begin Phase 2 Study in Early 2022; Reit Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

08/24/2021

Company Report

Pages: 5

Productive FDA Meeting Sets Pivotal Path for TTP399 in Motion; Reiterate Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

05/06/2021

Company Report

Pages: 4

Broad Clinical Progress Demonstrated in 1Q21; Reiterate Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

03/19/2021

Daily Note

Pages: 3

Mechanistic Study Initiated to Evaluate TTP399’s Effects on Diabetic Ketoacidosis

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

02/25/2021

Company Report

Pages: 5

Energy Rich Alberta Opens Runways for a Miner Carefully Governing its Bitcoin Holdings; Initial Coverage: Buy, C$14

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

12/15/2020

Daily Note

Pages: 3

Licensing Agreement Announced for Novel Nrf2 Activator HPP971 with Anteris Bio

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

11/09/2020

Company Report

Pages: 5

Characteristics of Patients in Elevage Suggest the Phase 2/3 is STEADFAST; Reiterate Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

09/23/2020

Daily Note

Pages: 3

Mechanism of Action Matters, So TTP399 May Be Better for Your Diabetes; Reiterate Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

08/14/2020

Company Report

Pages: 5

2Q20 Results and TTP399 Simplici-T1 Phase 2 Data in T1D; Reiterate Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/11/2020

Company Report

Pages: 4

TTP399 Still Simply Our Main Focus Near-Term; Reiterate Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

03/18/2020

Company Report

Pages: 5

TTP399 Simply the Highlight of Momentum Going Into 2020; Reiterate Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: vTv Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

02/10/2020

Company Report

Pages: 5

TTP399 May Simply Be a Breakthrough in T1D Treatment; Reiterate Buy With a New $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party